Ver­tex beefs up gene-edit­ing work with new dis­cov­ery pact; Ver­ri­ca shares jump on mol­lus­cum drug da­ta; J&J's inks two deals

→ Four months af­ter Ver­tex $VRTX and its al­lies at CRISPR Ther­a­peu­tics got start­ed on their first tri­al us­ing gene edit­ing tech for be­ta tha­lassemia, the Boston-based biotech is broad­en­ing its base in the field with a new re­search part­ner­ship. 

Ver­tex an­nounced Thurs­day morn­ing that it has drawn up a new pact in which Ar­bor Biotech­nolo­gies will fo­cus on dis­cov­er­ing pro­teins as they ad­vance gene-edit­ing tech on cys­tic fi­bro­sis and “four oth­er dis­eases to be se­lect­ed lat­er.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER